Semaglutide drugs: the facts behind the headlines

The misconception that all semaglutide products are the same thing

It's tempting to treat semaglutide as one monolithic drug that simply comes in different boxes. In reality, the product name carries the licence, and the licence determines what the medicine can legally be prescribed for. Ozempic is semaglutide, yes, but its UK licence covers type 2 diabetes management, not weight loss. A prescriber cannot lawfully supply Ozempic for weight management when a licensed alternative exists, and no legitimate pharmacy should. Wegovy (the injection and, since June 2026, the tablet) holds the weight-management licence, and that's the product range that belongs in a weight-management consultation.

The same applies to Rybelsus. It's oral semaglutide in 3 mg, 7 mg and 14 mg tablets, licensed for type 2 diabetes. People who come across it online and assume it's an alternative to the Wegovy tablet are working from an understandable but consequential misreading. If weight management is the goal, the relevant medicines are Wegovy, full stop. The full breakdown of which semaglutide products exist in the UK covers every brand and licence in detail.

There's also a broader misunderstanding worth addressing: that semaglutide drugs are a quick fix rather than a clinically supervised treatment. Every reputable guideline (including NICE's appraisal of Wegovy (TA875)) situates these medicines within a programme that includes dietary changes and increased activity. The drug reduces appetite; it doesn't replace the rest.

What semaglutide actually does in the body

Semaglutide belongs to a class of medicines called GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. It signals to your brain that you've had enough, slows the pace at which your stomach empties, and plays a role in how your body handles blood sugar. Semaglutide mimics this signal, and because it's designed to resist the enzymes that would normally break natural GLP-1 down quickly, it stays active in the body for around a week.

The practical effect is a reduction in appetite that many people describe as significant. Foods that previously triggered strong cravings become less compelling. Portion sizes that once felt inadequate start to feel sufficient. This is biology, not willpower, which is a point worth sitting with if you've struggled with weight for years and assumed you simply lacked self-discipline.

For a closer look at the GLP-1 drug class as a whole (including how semaglutide compares to other agents in it) that page covers the pharmacology in plain language. What matters for most people considering treatment is that the mechanism is well-studied and the clinical trial programme is large. The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults over 68 weeks and reported around 15% average weight reduction at 2.4 mg weekly.

The semaglutide drugs licensed for weight loss: injection, tablet and the NHS picture

Wegovy injection has been available in the UK since 2023. The titration starts at 0.25 mg weekly and is stepped up by the prescriber through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance dose, usually over about four to five months. A 7.2 mg maintenance dose was subsequently approved by the MHRA (the higher-dose pen received regulatory sign-off on 14 April 2026) for adults with a BMI of 30 or above. That dose narrows the average weight-loss gap between Wegovy and the dual-agonist tirzepatide.

The Wegovy tablet is newer still. It became the first oral GLP-1 medicine licensed in the UK for weight management when the MHRA approved it on 11 June 2026. It works with a different titration ladder (1.5 mg, 4 mg, 9 mg, then 25 mg) and needs to be taken first thing in the morning on an empty stomach, with a small amount of plain water, at least 30 minutes before food or other oral medicines. No fridge required. For people who find injections a barrier, it's a meaningful option, though the clinical decision about which format suits you belongs with a prescriber.

On the NHS, Wegovy is available through specialist weight management services under NICE TA875, though waiting lists are commonly long. Private treatment through a regulated pharmacy is the alternative for people who don't meet the NHS criteria or would rather not wait. If you're weighing up what private treatment costs, the Wegovy pricing page sets out the context honestly. A question our prescribers hear most weeks is whether there's a way to access semaglutide drugs faster, the short answer is that a legitimate private consultation is the only legal route outside the NHS pathway, and any seller offering these medicines without one is a red flag worth taking seriously.

Side effects, safety and when to get medical help

The most common side effects of semaglutide drugs are gastrointestinal. Nausea tends to be the one people encounter first, particularly after starting or moving to a higher dose. Vomiting, loose stools, constipation, reflux and fatigue also feature. For most people these settle within days to a couple of weeks; the slow titration schedule exists partly to give your system time to adjust.

Less common but worth knowing: pancreatitis is a recognised, if infrequent, risk with GLP-1 medicines. Severe stomach pain that radiates to the back (with or without vomiting) warrants urgent medical attention, not watchful waiting. The NHS semaglutide medicines page lists the full side-effect profile and the specific signs that need prompt care. Gallbladder symptoms and allergic reactions are also in the prescribing information and worth reading before you start.

Semaglutide weight-management medicines aren't suitable for everyone. Pregnancy, breastfeeding and actively trying to conceive are all reasons a prescriber would not supply them. Under-18s are outside the licensed population. Anyone with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 needs to discuss this before starting. These aren't formalities, they're the clinical checks that make supervised treatment different from ordering something unverified online. If you're curious about which specific medicines are actually classed as semaglutide, that page sets out the answer clearly, and if you'd like to explore other treatments that work in a similar way to semaglutide, that page explains the alternatives available. If you want to understand what a clinical assessment involves, the way our team works explains the process in detail.